OpenURL Connection Search

Select item for more details and to access through your institution.

Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype.
Published in:
Gene Therapy, 2010, v. 17, n. 9, p. 1105, doi. 10.1038/gt.2010.59
By:
- Neeson, P.;
- Shin, A.;
- Tainton, K. M.;
- Guru, P.;
- Prince, H. M.;
- Harrison, S. J.;
- Peinert, S.;
- Smyth, M. J.;
- Trapani, J. A.;
- Kershaw, M. H.;
- Darcy, P. K.;
- Ritchie, D. S.
Publication type:
Article
Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen.
Published in:
Gene Therapy, 2010, v. 17, n. 5, p. 678, doi. 10.1038/gt.2010.21
By:
- Peinert, S.;
- Prince, H. M.;
- Guru, P. M.;
- Kershaw, M. H.;
- Smyth, M. J.;
- Trapani, J. A.;
- Gambell, P.;
- Harrison, S.;
- Scott, A. M.;
- Smyth, F. E.;
- Darcy, P. K.;
- Tainton, K.;
- Neeson, P.;
- Ritchie, D. S.;
- Hönemann, D.
Publication type:
Article
Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice.
Published in:
Gene Therapy, 2008, v. 15, n. 14, p. 1056, doi. 10.1038/gt.2008.47
By:
- Westwood, J. A.;
- Murray, W. K.;
- Trivett, M.;
- Shin, A.;
- Neeson, P.;
- MacGregor, D. P.;
- Haynes, N. M.;
- Trapani, J. A.;
- Mayura-Guru, P.;
- Fox, S.;
- Peinert, S.;
- Honemann, D.;
- Prince, H. M.;
- Ritchie, D.;
- Scott, A. M.;
- Smyth, F. E.;
- Smyth, M. J.;
- Darcy, P. K.;
- Kershaw, M. H.
Publication type:
Article
Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models.
Published in:
Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-40852-3
By:
- Porter, L. H.;
- Zhu, J. J.;
- Lister, N. L.;
- Harrison, S. G.;
- Keerthikumar, S.;
- Goode, D. L.;
- Urban, R. Quezada;
- Byrne, D. J.;
- Azad, A.;
- Vela, I.;
- Hofman, M. S.;
- Neeson, P. J.;
- Darcy, P. K.;
- Trapani, J. A.;
- Taylor, R. A.;
- Risbridger, G. P.
Publication type:
Article
Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy.
Published in:
Clinical & Experimental Immunology, 2014, v. 175, n. 1, p. 49, doi. 10.1111/cei.12196
By:
- Chan, A. C.;
- Neeson, P.;
- Leeansyah, E.;
- Tainton, K.;
- Quach, H.;
- Prince, H. M.;
- Harrison, S. J.;
- Godfrey, D. I.;
- Ritchie, D.;
- Berzins, S. P.
Publication type:
Article
Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients.
Published in:
Leukemia (08876924), 2010, v. 24, n. 3, p. 592, doi. 10.1038/leu.2009.279
By:
- Chan, A C;
- Neeson, P;
- Leeansyah, E;
- Tainton, K;
- Quach, H;
- Prince, H M;
- Godfrey, D I;
- Ritchie, D;
- Berzins, S P
Publication type:
Article
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.
Published in:
2010
By:
- Quach, H.;
- Ritchie, D.;
- Stewart, A. K.;
- Neeson, P.;
- Harrison, S.;
- Smyth, M. J.;
- Prince, H. M.
Publication type:
journal article
Glofitamab plus R‐CHOP or polatuzumab vedotin‐R‐CHP is deliverable with high overall response in patients ≤65 years of age with high‐risk DLBCL: Interim analysis of COALITION.
Published in:
Hematological Oncology, 2023, v. 41, p. 421, doi. 10.1002/hon.3164_309
By:
- Minson, A.;
- Verner, E.;
- Giri, P.;
- Wong, S. M.;
- Ratnasingam, S.;
- Butler, J.;
- Janowski, W.;
- Ku, M.;
- Cheah, C. Y.;
- Hertzberg, M.;
- Herbert, K.;
- Hamad, N.;
- Yannakou, C. K.;
- Neeson, P.;
- Saghebi, J.;
- Blombery, P.;
- Robertson, M.;
- Lau, L. S.;
- Xie, J.;
- Seymour, J. F.
Publication type:
Article
PEMBROLIZUMAB AS FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD‐INELIGIBLE PATIENTS, ALLOWS SUBSEQUENT THERAPY, AND GIVES ADEQUATE SURVIVAL.
Published in:
Hematological Oncology, 2023, v. 41, p. 160, doi. 10.1002/hon.3163_106
By:
- Dickinson, M. J.;
- Trotman, J.;
- Berkahn, L.;
- Butler, J.;
- Bressel, M.;
- Neeson, P.;
- Minson, A.
Publication type:
Article
CD3bright signals on γδ T cells identify IL-17A-producing Vγ6Vδ1+ T cells.
Published in:
Immunology & Cell Biology, 2015, v. 93, n. 2, p. 198, doi. 10.1038/icb.2014.94
By:
- Paget, C;
- Chow, M T;
- Gherardin, N A;
- Beavis, P A;
- Uldrich, A P;
- Duret, H;
- Hassane, M;
- Souza‐Fonseca‐Guimaraes, F;
- Mogilenko, D A;
- Staumont‐Sallé, D;
- Escalante, N K;
- Hill, G R;
- Neeson, P;
- Ritchie, D S;
- Dombrowicz, D;
- Mallevaey, T;
- Trottein, F;
- Belz, G T;
- Godfrey, D I;
- Smyth, M J
Publication type:
Article
Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma.
Published in:
Scientific Reports, 2018, v. 8, n. 1, p. 1, doi. 10.1038/s41598-018-28944-3
By:
- Halse, H.;
- Colebatch, A. J.;
- Petrone, P.;
- Henderson, M. A.;
- Mills, J. K.;
- Snow, H.;
- Westwood, J. A.;
- Sandhu, S.;
- Raleigh, J. M.;
- Behren, A.;
- Cebon, J.;
- Darcy, P. K.;
- Kershaw, M. H.;
- McArthur, G. A.;
- Gyorki, D. E.;
- Neeson, P. J.
Publication type:
Article

Found: 11

Ex vivo culture of chimeric antigen receptor T cells generates functional CD8<sup>+</sup> T cells with effector and central memory-like phenotype.

Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen.

Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice.

Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models.

Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy.

Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients.

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Glofitamab plus R‐CHOP or polatuzumab vedotin‐R‐CHP is deliverable with high overall response in patients ≤65 years of age with high‐risk DLBCL: Interim analysis of COALITION.

PEMBROLIZUMAB AS FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD‐INELIGIBLE PATIENTS, ALLOWS SUBSEQUENT THERAPY, AND GIVES ADEQUATE SURVIVAL.

CD3<sup>bright</sup> signals on γδ T cells identify IL-17A-producing Vγ6Vδ1<sup>+</sup> T cells.

Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma.